How are beta‑D‑glucan (BDG) levels interpreted (negative, indeterminate, positive) and what clinical actions should be taken based on the result?

Beta-D-Glucan (BDG) Interpretation and Clinical Action

Serial BDG testing using thresholds of 80 pg/mL (high sensitivity) or 120 pg/mL (balanced sensitivity/specificity) should guide preemptive antifungal therapy in high-risk immunocompromised patients, but never rely on a single negative result to exclude invasive fungal infection, and always interpret positive results in the context of known false-positive triggers.

Understanding BDG Test Characteristics

BDG detects most clinically relevant fungi including Candida, Aspergillus, Pneumocystis, and Fusarium species, but notably does NOT detect Mucorales (mucormycosis) or Cryptococcus 1. This broad but incomplete coverage makes it a useful screening tool but requires integration with other diagnostics.

Threshold Interpretation

The evidence supports two main cutoff values:

• 80 pg/mL threshold: Sensitivity 89% (80-94%), Specificity 60% (54-66%) 2

  • Use for screening in high-risk populations
  • Minimizes false negatives but accepts more false positives
  • Detected 99% of proven invasive candidiasis cases 3

• 120 pg/mL threshold: Sensitivity 81% (71-88%), Specificity 80% (67-88%) 3

  • Use for diagnostic confirmation when specificity matters
  • Better balance for treatment decisions

Clinical Action Algorithm

For HIGH-RISK patients (neutropenia, hematologic malignancy, HSCT, solid organ transplant):

1. Negative BDG (<80 pg/mL):

   • Do NOT rule out invasive fungal infection based on single test 2
   • Continue serial monitoring (twice weekly recommended)
   • Consider if patient already on antifungals (decreases sensitivity) 1
   • Negative BDG makes Pneumocystis pneumonia highly unlikely 4

2. Indeterminate/Low-positive BDG (80-120 pg/mL):

   • Repeat testing within 24-48 hours
   • Investigate false-positive triggers (see below)
   • Add galactomannan testing for Aspergillus specificity
   • Obtain high-resolution chest CT if not already done
   • Consider BAL with GM and BDG testing 2

3. Positive BDG (>120 pg/mL):

   • Initiate preemptive mold-active antifungal therapy in appropriate clinical context 2, 4
   • Obtain additional diagnostics: galactomannan, imaging, BAL
   • Serial testing to monitor treatment response (declining levels suggest success) 1

For LOW-RISK patients:

BDG testing is NOT recommended 2. The low pretest probability combined with modest specificity leads to unacceptable false-positive rates that trigger unnecessary antifungal therapy.

Critical False-Positive Triggers

You must actively exclude these before acting on positive BDG:

• Hemodialysis with cellulose membranes 2
• Blood products: albumin, IVIG, fresh frozen plasma, packed red blood cells 2, 5
  • BDG levels in blood products directly predict post-transfusion false positives 5
• Bacterial infections: Particularly Gram-negative bacteremia (Pseudomonas, E. coli) with 59% false-positive rate 1, 6
• Antibiotics: Piperacillin-tazobactam, penicillin G (continuous high-dose) 2, 7
• Gauze exposure: Glucan-containing surgical gauze in contact with blood 1
• Food aspiration: Rice and other glucan-containing foods can cause transient elevation 8

Common Pitfalls to Avoid

1. Single test reliance: Sensitivity of single serum test is extremely low 2. Always use serial monitoring.

2. Testing on antifungals: Prior antifungal therapy significantly decreases BDG sensitivity 1. A negative result in this context is unreliable. However, a positive result despite ongoing therapy is highly meaningful and suggests persistent infection or treatment failure.

3. Species-specific limitations:

   • Candida auris releases significantly less BDG than other Candida species (24% reactivity vs. C. albicans), resulting in only 60% sensitivity 9
   • Always negative in mucormycosis and cryptococcosis 1

4. Ignoring clinical context: BDG elevation with Gram-negative bacteremia, recent transfusions, or dialysis should prompt investigation of these causes before assuming fungal infection 1, 6.

5. Delayed imaging: High-resolution chest CT should be obtained within 24 hours of clinical suspicion 4. BDG positivity combined with halo sign on CT warrants immediate antifungal therapy.

Integration with Other Tests

BDG is not mycologically specific 1. Combine with:

• Galactomannan for Aspergillus specificity (but note GM also cross-reacts with Histoplasma, Fusarium, Penicillium) 1
• Culture and microscopy remain essential for species identification
• BAL fluid testing superior to serum for pulmonary infections 2

The most recent 2025 guideline emphasizes that serial testing patterns matter more than single values: rising or persistently positive BDG indicates treatment failure, while declining levels suggest therapeutic success 1.